Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;30(6):3125-3136.
doi: 10.1007/s00330-019-06647-1. Epub 2020 Feb 21.

SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging

Affiliations

SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging

Esha Baidya Kayal et al. Eur Radiol. 2020 Jun.

Abstract

Objective: Histopathological examination (HPE) is the current gold standard for assessing chemotherapy response to tumor, but it is possible only after surgery. The purpose of the study was to develop a noninvasive, imaging-based robust method to delineate, visualize, and quantify the proportions of necrosis and viable tissue present within the tumor along with peritumoral edema before and after neoadjuvant chemotherapy (NACT) and to evaluate treatment response with correlation to HPE necrosis after surgery.

Methods: The MRI dataset of 30 patients (N = 30; male:female = 24:6; age = 17.6 ± 2.7 years) with osteosarcoma was acquired using 1.5 T Philips Achieva MRI scanner before (baseline) and after 3 cycles of NACT (follow-up). After NACT, all patients underwent surgical resection followed by HPE. Simple linear iterative clustering supervoxels and Otsu multithresholding were combined to develop the proposed method-SLICs+MTh-to subsegment and quantify viable and nonviable regions within tumor using multiparametric MRI. Manually drawn ground-truth ROIs and SLICs+MTh-based segmentation of tumor, edema, and necrosis were compared using Jacquard index (JI), Dice coefficient (DC), precision (P), and recall (R). Postcontrast T1W images (PC-T1W) were used to validate the SLICs+MTh-based necrosis. SLICs+MTh-based necrosis volume at follow-up was compared with HPE necrosis using paired t test (p ≤ 0.05).

Results: Active tumor, necrosis, and edema were segmented with moderate to satisfactory accuracy (JI = 62-78%; DC = 72-87%; P = 67-87%; R = 63-88%). Qualitatively and quantitatively (DC = 74 ± 9%), the SLICs+MTh-based necrosis area correlated well with the hypointense necrosis areas in PC-T1W. No significant difference (paired t test, p = 0.26; Bland-Altman plot, bias = 2.47) between SLICs+MTh-based necrosis at follow-up and HPE necrosis was observed.

Conclusion: The proposed multiparametric MRI-based SLICs+MTh method performs noninvasive assessment of NACT response in osteosarcoma that may improve cancer treatment monitoring, planning, and overall prognosis.

Key points: • The simple linear iterative clustering supervoxels and Otsu multithresholding-based technique (SLICs+MTh) successfully estimates the proportion of necrosis, viable tumor, and edema in osteosarcoma in the course of chemotherapy. • The proposed technique is noninvasive and uses multiparametric MRI to measure necrosis as an indication of anticancer treatment response. • SLICs+MTh-based necrosis was in satisfactory agreement with histological necrosis after surgery.

Keywords: Chemotherapy; Computer-assisted decision-making; Magnetic resonance imaging; Osteosarcoma; Treatment outcome.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31. https://doi.org/10.3322/canjclin.49.1.8 - DOI - PubMed
    1. Bacci G, Picci P, Ferrari S et al (1993) Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72:3227–3238. https://doi.org/10.1002/1097-0142(19931201)72:11<3227::AID-CNCR282072... - DOI - PubMed
    1. Bacci G, Briccoli A, Ferrari S et al (2001) Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 37:2030–2039. https://doi.org/10.1016/S0959-8049(01)00229-5 - DOI - PubMed
    1. Wittig JC, Bickels J, Priebat D et al (2002) Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 65:1123–1132. https://doi.org/10.1111/j.1529-8019.2010.01352.x - DOI - PubMed
    1. Wang C, Du L, Si M et al (2013) Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study. PLoS One 8:e72679. https://doi.org/10.1371/journal.pone.0072679 - DOI - PubMed - PMC

Substances

LinkOut - more resources